Mechanism research has shown that the atezolizumab plus bevacizumab combination can synergistically produce the following effects: 1) inhibiting angiogenesis; 2) reducing the infiltration of myeloid-derived suppressor cells (MDSCs) and adjusting the ratio of M1/M2 tumor-associated macrophages (TAMs); 3) promoting the infiltration and functional recovery of CD8+ T cells (CTLs) 11. Here, CD8A is linked to neoplasm.